11 completed, 1 withdrawn. 12 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 11, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Statens Serum Institut: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence H56:IC31, Placebo - Tuberculosis, Pulmonary | Phase 2 | Completed | International AIDS Vaccine Initiative | 831 | 2019-01-31 | 2026-02-24 |
| A Phase II Study of H56:IC31 in Healthy Adolescents H56:IC31, Placebo - Tuberculosis Infection | Phase 2 | Withdrawn | Aeras | 2018-06-01 | 2018-04-10 | |
| 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI, IPV Vaccine SSI - Poliomyelitis | Phase 2 | Completed | Statens Serum Institut | 824 | 2015-02-01 | 2018-11-14 |
| 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents 1/3 IPV-Al SSI, manufactured by SSI, Denmark, 1/5 IPV-Al SSI, manufactured by SSI, Denmark, 1/10 IPV-Al SSI, manufactured by SSI, Denmark - Immunization, Booster | Phase 1 / Phase 2 | Completed | Statens Serum Institut | 240 | 2014-11-13 | 2018-11-14 |
| Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses C-Tb, Tuberculin PPD RT 23 SSI, C-Tb / Tuberculin PPD RT 23 SSI - Tuberculosis | Phase 2 / Phase 3 | Completed | Statens Serum Institut | 456 | 2013-10-01 | 2015-04-17 |
| A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456) H56ug/IC31nmol, Placebo - Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Aeras | 98 | 2013-08-01 | 2019-12-19 |
| Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants AERAS-404, Placebo - Tuberculosis | Phase 1 / Phase 2 | Completed | Aeras | 243 | 2013-07-01 | 2018-04-09 |
| A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG C-Tb, 2 TU Tuberculin PPD RT 23 SSI - Tuberculosis | Phase 2 | Completed | Statens Serum Institut | 151 | 2011-04-01 | 2013-01-21 |
| A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB) C-Tb, 2 TU Tuberculin PPD RT 23 SSI - Tuberculosis | Phase 2 | Completed | Statens Serum Institut | 253 | 2011-04-01 | 2015-04-17 |
| Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study Trichuris suis ova - Relapsing Multiple Sclerosis | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 10 | 2010-05-01 | 2011-11-10 |
| Therapeutic Zinc in Childhood Pneumonia Zinc (zinc sulphate), Placebo - Pneumonia | Phase 2 / Phase 3 | Completed | Centre For International Health | 641 | 2006-01-01 | 2009-10-06 |
| CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia Zinc - Pneumonia | Phase 2 / Phase 3 | Completed | Centre For International Health | 2628 | 2004-01-01 | 2022-03-16 |
Tuberculosis (5) · Latent Tuberculosis (2) · Pneumonia (2) · Multiple Sclerosis (1) · Poliomyelitis (1) · Recurrence (1) · Reinfection (1) · Tuberculosis, Pulmonary (1)
Tuberculin (2) · Zinc (2) · Zinc Sulfate (1)
South Africa (6) · Denmark (2) · Nepal (2) · Tanzania (2) · Dominican Republic (1) · United Kingdom (1)
Birgit Thierry-Carstensen (2) · Dereck Tait, MD (2) · Angelique Luabeya, MD (1) · Ann Ginsberg, MD, PhD (1) · Avy Violari, MD (1) · David JM Lewis, MD (1) · Halvor Sommerfelt, MD PhD (1) · Halvor Sommerfelt, MD, PhD (1) · Ingrid Kromann (1) · Keertan Dheda, MD (1) · Keertan Dheda, MD, Prof (1) · Line Markdanner Lindgren (1) · Marissa Russell (1) · Nita Bhandari, MBBS, PhD (1) · Palle Valentiner-Branth, MD PhD (1)
PMID 20375190, PMID 22392179, PMID 23691171, PMID 25698173, PMID 26407163, PMID 26677940, PMID 28027810, PMID 28454674, PMID 28678771, PMID 30092143, PMID 30572979, PMID 40056922, PMID 42482138
2014 (2), 2009 (1), U01AI068632 (1)